Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 38 of 38 entries
View as:

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05200169 Org: User:
Start: 07/31/17 End: 09/01/17 Due: 09/01/18

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Phase: N/A Priority: Normal
NCT ID: NCT00831974 Org: User:
Start: 10/31/04 End: - Due: -

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Phase: N/A Priority: Normal
NCT ID: NCT01280565 Org: User:
Start: 01/31/11 End: 08/31/19 Due: 08/31/20

Masitinib Plus Gemcitabine in Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03766295 Org: User:
Start: 07/31/14 End: 12/31/20 Due: 12/31/21

Masitinib in Refractory Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01410695 Org: User:
Start: 07/31/11 End: 10/31/15 Due: 10/31/16

Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04622865 Org: User:
Start: 06/01/20 End: 12/31/23 Due: 12/31/24

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05211570 Org: User:
Start: 06/01/22 End: 12/31/24 Due: 12/31/25

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05441488 Org: User:
Start: 06/28/22 End: 12/31/25 Due: 12/31/26

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04333108 Org: User:
Start: 07/01/20 End: 06/30/25 Due: 06/30/26

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01266369 Org: User:
Start: 02/28/07 End: 05/31/10 Due: 05/31/11

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Phase: N/A Priority: Normal
NCT ID: NCT00998751 Org: User:
Start: 06/30/05 End: 06/30/13 Due: 06/30/14

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02605044 Org: User:
Start: 01/31/14 End: 12/31/17 Due: 12/31/18

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Phase: N/A Priority: Normal
NCT ID: NCT01506336 Org: User:
Start: 10/31/08 End: 04/30/12 Due: 04/30/13